Introduction
The use of the MitraClip (Abbott Vascular, Abbott Park, IL, USA) system in patients with severe degenerative mitral regurgitation (MR) and prohibitive surgical risk has been well established. [1] [2] [3] [4] Percutaneous mitral valve plication using the MitraClip device has recently emerged as a treatment option in patients with symptomatic obstructive hypertrophic cardiomyopathy (HOCM) to eliminate systolic anterior motion (SAM) of the mitral valve and reduce left ventricular outflow tract (LVOT) gradients. [5] [6] [7] [8] We report a patient with
Learning points
• Transcatheter edge-to-edge repair of the mitral valve using the MitraClip system is effective in treating severe degenerative mitral regurgitation.
• Percutaneous mitral valve plication using the MitraClip system is a feasible treatment alternative for systolic anterior motion of the mitral valve in obstructive hypertrophic cardiomyopathy (HOCM).
• In patients with concomitant HOCM and primary mitral valve disease, the use of MitraClip could be a possible alternative to surgical septal reduction with mitral valve repair/replacement. 
Timeline Case summary
A 76-year-old lady with history of dyslipidaemia, cerebrovascular accident, and prior surgical resection of rectal adenocarincoma was followed up in our centre for HOCM and atrial fibrillation (AF). Her medications included sustained release Verapamil 240 mg once daily, Bisoprolol 2.5 mg once daily, Simvastatin 40 mg every night, and Warfarin titrated to an international normalized ratio target of 2-3. Pre-morbidly, she was functionally in New York Heart Association Classification II-III but spent most of her time at home and experienced no symptoms ambulating around. She had no prior heart failure admissions until the recent 2 months when she was admitted on five occasions for angina and dyspnoea on exertion. Other symptoms included orthopnoea and paroxysmal nocturnal dyspnoea but no giddiness or syncopal episodes. Physical examination showed a pulse rate of 76 b.p.m., blood pressure of 126/72 mmHg, respiratory rate of 16/min, and 98% oxygen saturation. Auscultation revealed a pansystolic murmur over the apex as well as an ejection systolic murmur over the upper left sternal border. There were mild bibasal lung crepitations and no pedal oedema. Medical management over the 2 months was difficult due to the effect of diuresis on LVOT obstruction and resultant angina. Surgical management would be complicated in view of the small LVOT size and the need for dual valve replacement (MR and AR). Importantly, several senior surgeons felt that there would be significant interaction between any prosthetic valves and the LVOT. In addition, her logistic EuroSCORE was 7.64%. Alcohol septal ablation and pacing only addresses SAM and not the flail leaflet. After a Heart Team discussion, decision was made to offer transcatheter intervention using the MitraClip system to fix the flail P2. Concomitantly in the same procedure, we could address the issue of SAM and LVOT obstruction and hopefully improve her baseline functional status. The first clip was placed centrally over the flail P2 segment with reduction of MR grade from 4þ to 2þ (Figure 3 , Supplementary material online, Video S4). The residual MR was located at the A1 segment. The MR jet was posteriorly directed and was SAM-related. Decision was made to deploy a second clip lateral to the first clip. There was initially some difficulty grasping the anterior mitral valve leaflet but after multiple attempts, the second clip was deployed successfully ( Figure 4A ). This reduced the MR grade further to 1-2þ ( Figure 4B , Supplementary material online, Videos S5-S7) and a reduction in LVOT gradient to 33 mmHg ( Figure 4C,D) . The systolic blood pressure improved significantly post-procedure from 90 mmHg to 160 mmHg.
Post-procedure, she experienced a significant improvement in symptoms and was discharged well to a step-down facility for continued rehabilitation. Unfortunately, she had repeated admissions for upper gastrointestinal bleeding. After multiple endoscopic evaluations, it was found on capsule endoscopy to be due to jejunal angiodysplasia, and this was successfully treated with double balloon enteroscopy and ablation. Her symptoms improved but she developed AF with rapid ventricular rate which resulted in readmission for chest pain and dyspnoea. Transthoracic echocardiogram at 1 and 6 months showed that both clips were stable with an overall MR grade of 2þ. The LVOT gradient remained lower at 38 mmHg, but there was no significant change in pulmonary artery systolic pressures.
Discussion
MitraClip for the treatment of degenerative MR and prohibitive surgical risk is well established and has an excellent safety profile. case reports which showcase the utility of this treatment in such patients.
In patients with symptomatic HOCM refractory to maximal medical therapy, invasive septal reduction therapy (surgical septal myectomy or alcohol septal ablation) is indicated. 12 Mitral valve repair or replacement may have to be performed at time of septal myectomy in patients with primary mitral valve disease. 13 In patients who are not candidates for septal reduction therapy or deemed high risk for open heart surgery, percutaneous mitral valve plication with the MitraClip device has emerged in recent years as a potential alternative treatment modality. Firstly, initial reports have demonstrated its efficacy in improving symptoms, LVOT gradient and MR grade.
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Thomas et al. 8 compiled data of four studies conducted from 2010 to 2016 on 15 patients with symptomatic HOCM who underwent the MitraClip procedure. All patients experienced symptomatic relief, an improvement in MR and resolution of SAM. There was a reduction in mean LVOT gradients from 75.8 ± 39.7 mmHg to 11.0 ± 5.6 mmHg. Secondly, MitraClip may be a safer option compared to alcohol septal ablation in patients who are poor surgical candidates. Alcohol septal ablation is associated with risks of complete heart block, 14 as well as ventricular arrhythmias originating from the infarcted myocardium. 15 Lastly, MitraClip is not dependent on coronary anatomy or degree of septal hypertrophy.
Conclusion
We report a case that demonstrated the feasibility of the MitraClip system to treat not just degenerative MR but also SAM from HOCM in a single procedure.
Supplementary material
Supplementary material is available at European Heart Journal -Case Reports online.
Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.
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